Skip to content

Released Aug 4, 2021, after the close

10-Q filed Aug 4, 2021, 35 days after period end · 0001564590-21-040821

Q2 2021 · 10-Q
Revenue$13.41M+145.4% vs Q2 2020+20.4% vs Q1 2021
Net Income-$55.13MN/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.58N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$46,779,000N/M
Operating Cash Flowderived-$32,106,000N/M
Free Cash Flowderived-$45,725,000N/M
Margins · derived
Operating margin-348.8%+176.5 pt vs Q2 2020
Net margin-411.1%+102.6 pt vs Q2 2020

What the release said

The release

Same quarter

MetricQ2 2021Q2 2020Q2 2019Q2 2018
Revenue$13.41M$5.47M$2.82M$1.03M
Net Income-$55.13M-$28.07M-$23.48M-$19.65M
EPS Diluted-$0.58-$0.35-$0.36-$0.37

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR